We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000880:KRXHanwha Corporation Analysis

Data as of 2026-03-07 - not real-time

₩132,600.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Hanwha Corporation (000880.KS) is trading well above its 20‑, 50‑ and 200‑day SMAs (124k, 111k and 91k respectively), confirming a bullish price trend. The RSI sits at 56.7, indicating neutral‑to‑slightly bullish momentum, while the MACD histogram is negative (MACD line below signal), suggesting short‑term bearish pressure. The stock’s forward P/E of 7.95 is dramatically lower than the industry average of 29.37, and the DCF‑derived fair value of roughly 632k KRW implies a ~10% upside from the current price of 132.6k KRW. Revenue is expanding at a robust 45.6% YoY, but margins remain thin (gross 14.2%, operating 7.6%, profit 1.7%) and the balance sheet is heavily leveraged with a debt‑to‑equity ratio of 133.
Despite the high leverage, the company holds ample cash (≈63T KRW) and pays a modest dividend (0.83% yield, 5.9% payout), supporting dividend sustainability. Volatility is elevated at 91% over the past 30 days, yet beta is low (~0.68), indicating limited systematic risk. Volume is trending higher, reinforcing the bullish bias, while no material news items currently shift the outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • MACD histogram negative indicating short‑term bearish pressure
  • Price already above key moving averages providing support
  • Elevated 30‑day volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth (45.6% YoY)
  • Significant valuation discount vs industry (forward P/E 7.95 vs 29.37)
  • Increasing trading volume supporting bullish trend

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued DCF fair value suggesting upside potential
  • Low dividend payout ratio and ample cash buffer
  • Diversified conglomerate structure reducing single‑segment exposure

Key Metrics & Analysis

Financial Health

Revenue Growth45.60%
Profit Margin1.74%
P/E Ratio7.9
ROE8.91%
ROA1.21%
Debt/Equity133.08
Op. Cash Flow₩9598.8B
Free Cash Flow₩1434.6B
Industry P/E29.4

Technical Analysis

TrendBullish
RSI56.7
Support₩107,000.00
Resistance₩148,500.00
MA 20₩124,425.00
MA 50₩110,554.00
MA 200₩91,375.00
MACDBearish
VolumeIncreasing
Fear & Greed Index68.77

Valuation

Fair Value₩632,496.11
Target Price₩146,400.00
Upside/Downside10.41%
GradeUndervalued
TypeBlend
Dividend Yield0.83%

Risk Assessment

Beta0.68
Volatility91.47%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.